| Quarter | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| 10 | 33 | 33 | |
Growth YoY Revenue Growth YoY% | 237.5 | ||
| 9 | 30 | 31 | |
| 0 | 3 | 2 | |
OPM OPM% | 3.4 | 8.8 | 6.0 |
| 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 |
PBT PBTCr | 0 | 3 | 2 |
| 0 | 1 | 0 | |
| 0 | 2 | 1 | |
Growth YoY PAT Growth YoY% | 753.3 | ||
NPM NPM% | 1.6 | 5.5 | 3.9 |
| 0.1 | 1.2 | 0.8 |
| Quarter | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| 10 | 33 | 33 | |
Growth YoY Revenue Growth YoY% | 237.5 | ||
| 9 | 30 | 31 | |
| 0 | 3 | 2 | |
OPM OPM% | 3.4 | 8.8 | 6.0 |
| 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 |
PBT PBTCr | 0 | 3 | 2 |
| 0 | 1 | 0 | |
| 0 | 2 | 1 | |
Growth YoY PAT Growth YoY% | 753.3 | ||
NPM NPM% | 1.6 | 5.5 | 3.9 |
| 0.1 | 1.2 | 0.8 |
| Financial Year | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
Revenue RevenueCr | 15 | 42 | 65 |
Growth Revenue Growth% | 185.3 | ||
| 14 | 39 | 60 | |
| 1 | 3 | 5 | |
OPM OPM% | 5.3 | 7.5 | 7.4 |
| 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 1 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 |
PBT PBTCr | 0 | 3 | 5 |
| 0 | 1 | 1 | |
PAT PATCr | 0 | 2 | 3 |
Growth PAT Growth% | 777.3 | ||
NPM NPM% | 1.5 | 4.6 | 4.7 |
| 0.2 | 1.4 | 2.0 |
| Financial Year | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
Revenue RevenueCr | 15 | 42 | 65 |
Growth Revenue Growth% | 185.3 | ||
| 14 | 39 | 60 | |
| 1 | 3 | 5 | |
OPM OPM% | 5.3 | 7.5 | 7.4 |
| 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 1 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 |
PBT PBTCr | 0 | 3 | 5 |
| 0 | 1 | 1 | |
PAT PATCr | 0 | 2 | 3 |
Growth PAT Growth% | 777.3 | ||
NPM NPM% | 1.5 | 4.6 | 4.7 |
| 0.2 | 1.4 | 2.0 |
| Financial Year | Mar 2026 | Sep 2026 |
|---|---|---|
Equity Capital Equity CapitalCr | 15 | 15 |
Reserves ReservesCr | 13 | 14 |
| 35 | 39 | |
| 35 | 39 |
| Financial Year | Mar 2026 | Sep 2026 |
|---|---|---|
Equity Capital Equity CapitalCr | 15 | 15 |
Reserves ReservesCr | 13 | 14 |
| 35 | 39 | |
| 35 | 39 |
| Financial Year | Mar 2026 |
|---|---|
| 1 | |
| 0 | |
| 1 | |
Net Cash Flow Net Cash FlowCr | 1 |
Free Cash Flow Free Cash FlowCr | |
CFO To PAT CFO To PAT% | 36.3 |
CFO To EBITDA CFO To EBITDA% | 21.9 |
| Financial Year | Mar 2026 |
|---|---|
| 1 | |
| 0 | |
| 1 | |
Net Cash Flow Net Cash FlowCr | 1 |
Free Cash Flow Free Cash FlowCr | |
CFO To PAT CFO To PAT% | 36.3 |
CFO To EBITDA CFO To EBITDA% | 21.9 |
| Financial Year | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|
Market Cap Market CapitalizationCr | 56 | 80 | |
Price To Earnings Price To Earnings | 29.0 | 26.2 | |
Price To Sales Price To Sales | 1.3 | 1.2 | |
Price To Book Price To Book | 2.0 | 2.8 | |
EV To EBITDA EV To EBITDA | 17.1 | 16.4 | |
GPM GPM% | |||
OPM OPM% | 5.3 | 7.5 | 7.4 |
NPM NPM% | 1.5 | 4.6 | 4.7 |
ROCE ROCE% | 10.2 | 16.2 | |
ROE ROE% | 6.8 | 10.3 | |
ROA ROA% | 5.5 | 7.8 | |
| Financial Year | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|
Market Cap Market CapitalizationCr | 56 | 80 | |
Price To Earnings Price To Earnings | 29.0 | 26.2 | |
Price To Sales Price To Sales | 1.3 | 1.2 | |
Price To Book Price To Book | 2.0 | 2.8 | |
EV To EBITDA EV To EBITDA | 17.1 | 16.4 | |
GPM GPM% | |||
OPM OPM% | 5.3 | 7.5 | 7.4 |
NPM NPM% | 1.5 | 4.6 | 4.7 |
ROCE ROCE% | 10.2 | 16.2 | |
ROE ROE% | 6.8 | 10.3 | |
ROA ROA% | 5.5 | 7.8 | |
| Market CapitalizationMkt CapCr | 230 | 149 | 128 | 123 | 90 | 80 | 72 |
| Close PriceClose₹ | 207.00 | 135.00 | 158.00 | 57.08 | 68.51 | 52.75 | 39.45 |
| IndustryIndustry | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS |
| Price To EarningsPE | 17.54 | 17.26 | 17.34 | 29.66 | 26.24 | 43.83 | |
| Price To SalesPS | 2.28 | 1.09 | 1.83 | 4.58 | 0.93 | 1.23 | 0.91 |
| RevenueRevenueCr | 101 | 137 | 70 | 27 | 97 | 65 | 78 |
| Revenue Growth TTMRev Gr TTM% | 22.3% | 54.7% | -1.4% | 114.4% | 17.9% | ||
| PAT Growth TTMPAT Gr TTM% | 44.5% | -3.4% | 51.4% | 410.3% | 52.3% |
| Market CapitalizationMkt CapCr | 230 | 149 | 128 | 123 | 90 | 80 | 72 |
| Close PriceClose₹ | 207.00 | 135.00 | 158.00 | 57.08 | 68.51 | 52.75 | 39.45 |
| IndustryIndustry | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS |
| Price To EarningsPE | 17.54 | 17.26 | 17.34 | 29.66 | 26.24 | 43.83 | |
| Price To SalesPS | 2.28 | 1.09 | 1.83 | 4.58 | 0.93 | 1.23 | 0.91 |
| RevenueRevenueCr | 101 | 137 | 70 | 27 | 97 | 65 | 78 |
| Revenue Growth TTMRev Gr TTM% | 22.3% | 54.7% | -1.4% | 114.4% | 17.9% | ||
| PAT Growth TTMPAT Gr TTM% | 44.5% | -3.4% | 51.4% | 410.3% | 52.3% |